These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 25406147

  • 21. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
    Beasley BN, Unger EF, Temple R.
    N Engl J Med; 2011 May 12; 364(19):1788-90. PubMed ID: 21488759
    [No Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 May 12; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV, Gage BF.
    Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397
    [Abstract] [Full Text] [Related]

  • 24. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar 07; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 25. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Edwards DB, Silverberg J.
    Ann Intern Med; 2011 Apr 19; 154(8):570; author reply 570-1. PubMed ID: 21502658
    [No Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H, Johnston SC, Easton JD, Kim AS.
    Stroke; 2012 Mar 19; 43(3):881-3. PubMed ID: 22308255
    [Abstract] [Full Text] [Related]

  • 27. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.
    Am J Cardiol; 2013 Aug 01; 112(3):387-9. PubMed ID: 23647794
    [Abstract] [Full Text] [Related]

  • 28. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF.
    Nat Rev Nephrol; 2015 Jan 01; 11(1):3. PubMed ID: 25421829
    [No Abstract] [Full Text] [Related]

  • 29. Dabigatran and postmarketing reports of bleeding.
    Southworth MR, Reichman ME, Unger EF.
    N Engl J Med; 2013 Apr 04; 368(14):1272-4. PubMed ID: 23484796
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.
    Circulation; 2014 Mar 04; 129(9):961-70. PubMed ID: 24323795
    [Abstract] [Full Text] [Related]

  • 31. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Panchenko EP.
    Kardiologiia; 2011 Mar 04; 51(11):83-90. PubMed ID: 22117775
    [No Abstract] [Full Text] [Related]

  • 32. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Hirano T.
    Circ J; 2014 Mar 04; 78(6):1317-9. PubMed ID: 24805358
    [No Abstract] [Full Text] [Related]

  • 33. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A, Bailey C, Abdelhafiz AH.
    Age Ageing; 2012 Sep 04; 41(5):681-4. PubMed ID: 22378612
    [Abstract] [Full Text] [Related]

  • 34. Atrial fibrillation in 2010: advances in treatment and management.
    Connolly SJ.
    Nat Rev Cardiol; 2011 Feb 04; 8(2):67-8. PubMed ID: 21270842
    [Abstract] [Full Text] [Related]

  • 35. [Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
    Einecke D.
    MMW Fortschr Med; 2014 Dec 15; 156(21-22):28, 30. PubMed ID: 25608388
    [No Abstract] [Full Text] [Related]

  • 36. Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
    Henriksen DP, Hansen MR, Damkier P.
    JAMA Intern Med; 2015 Jul 15; 175(7):1245. PubMed ID: 26146921
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
    Freeman WD, Kuo R, Aguilar MI.
    Stroke; 2012 Jul 15; 43(7):e63. PubMed ID: 22618385
    [No Abstract] [Full Text] [Related]

  • 39. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    Klil-Drori A, Azoulay L.
    JAMA Intern Med; 2015 Jul 15; 175(7):1243-4. PubMed ID: 26146918
    [No Abstract] [Full Text] [Related]

  • 40. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM.
    Heart Lung; 2014 Jul 15; 43(1):48-59. PubMed ID: 24373340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.